杭州昊鑫生物科技股份有限公司
网站标题
搜索

取消

清空记录

历史记录

清空记录

历史记录

清空记录

历史记录

杭州昊鑫生物科技股份有限公司
    当前位置:
  • 首页>
  • 产品中心>
  • MCE>
  • Rapamycin(Synon...

Rapamycin(Synonyms: 雷帕霉素; 西罗莫司; Sirolimus; AY-22989)

分享到微信

×
Rapamycin (Sirolimus) 是一种有效且特异性的 mTOR 抑制剂,作用于 HEK293 细胞,抑制 mTOR,IC50 为 0.1 nM。Rapamycin 与 FKBP12 结合且抑制 mTORC1。Rapamycin 还是一种自噬 (autophagy) 激活剂,免疫抑制剂。
参数品牌:MCE
产品参数
品牌:MCE
型号:HY-10219
规格:10mg
价格:550.000
我知道了
产品详情

Rapamycin (Sirolimus) 是一种有效且特异性的 mTOR 抑制剂,作用于 HEK293 细胞,抑制 mTOR,IC50 为 0.1 nM。Rapamycin 与 FKBP12 结合且抑制 mTORC1。Rapamycin 还是一种自噬 (autophagy) 激活剂,免疫抑制剂。


生物活性
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].
IC50 & Target[1][2]
mTOR:0.1 nM (IC50, in HEK293 cells )

 


体外研究
(In Vitro)


Rapamycin (12.5-100 nM; 24 hours) treatment exerts modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines (A549, SPC-A-1, 95D and NCI-H446 cells) tested, achieving about 30-40% reduction in cell proliferation at 100 nM vs. ~10% reduction at 12.5 nM[3].
Lung cancer cell line 95D cells are exposed to Rapamycin (10 nM, 20 nM) and RP-56976 (1 nM, 10 nM) alone or in combination (Rapamycin 20 nM+ RP-56976 10 nM). After 24 hours exposure to Rapamycin or RP-56976 alone does not significantly alter the level of expression or phosphorylation of ERK1/2, whereas cells treated with the combination of Rapamycin with RP-56976 exhibit a marked reduction in the phosphorylation levels of ERK1/2[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3]

Cell Line: Lung cancer cell lines A549, SPC-A-1, 95D and NCI-H446
Concentration: 12.5 nM, 25 nM, 50 nM, 100 nM
Incubation Time: 24 hours
Result: Treatment exerted modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines.



体内研究
(In Vivo)


Rapamycin (2.0 mg/kg; intraperitoneal injection; every other day; 28 days) alone has a moderate inhibitory effect. However, the combination of Metformin and Rapamycin exerts a significantly increased inhibition of tumor growth compared with the control group, the Rapamycin monotherapy group and the Metformin monotherapy group[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 24 male nu/nu mice aged 4-5 week old (15-20 g)[4]
Dosage: 2.0 mg/kg
Administration: Intraperitoneal injection; every other day; 28 days
Result: Had a moderate inhibitory effect in monotherapy group. The combination with Metformin exerted a significantly increased inhibition of tumor growth.



Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01885689 City of Hope Medical Center|National Cancer Institute (NCI)
Adult Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Therapy-Related Myelodysplastic Syndrome
February 10, 2014 Phase 2
NCT04893291 Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Artery Disease|Coronary Artery Stenosis
October 30, 2021 Not Applicable
NCT03582878 Institute for Clinical and Experimental Medicine
Diabetes Mellitus, Type 1
January 1, 2004 Phase 4

分子量
914.17
CAS 号
53123-88-9
Formula
C51H79NO 13
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

溶解性数据


In Vitro: 

DMSO : 125 mg/mL (136.74 mM; Need ultrasonic)

Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic)

配制储备液
浓度溶剂体积质量 1 mg 5 mg 10 mg
1 mM 1.0939 mL 5.4694 mL 10.9389 mL
5 mM 0.2188 mL 1.0939 mL 2.1878 mL
10 mM 0.1094 mL 0.5469 mL 1.0939 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% EtOH    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.73 mM); Suspended solution

  • 2.

    请依序添加每种溶剂: 10% EtOH    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (2.73 mM); Suspended solution; Need ultrasonic

  • 3.

    请依序添加每种溶剂: 10% EtOH    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.73 mM); Suspended solution

  • 4.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (2.28 mM); Clear solution

  • 5.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (2.28 mM); Suspended solution; Need ultrasonic

  • 6.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (2.28 mM); Clear solution



参考文献


[1]. Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282(18), 13395-13401.

[2]. Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25;30(34):11388-97.

[3]. Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30:28.

[4]. Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15(2):1811-1816.



Rapamycin(Synonyms: 雷帕霉素; 西罗莫司; Sirolimus; AY-22989)
Rapamycin(Synonyms: 雷帕霉素; 西罗莫司; Sirolimus; AY-22989)

Rapamycin(Synonyms: 雷帕霉素; 西罗莫司; Sirolimus; AY-22989)

分享到微信

×
Rapamycin (Sirolimus) 是一种有效且特异性的 mTOR 抑制剂,作用于 HEK293 细胞,抑制 mTOR,IC50 为 0.1 nM。Rapamycin 与 FKBP12 结合且抑制 mTORC1。Rapamycin 还是一种自噬 (autophagy) 激活剂,免疫抑制剂。
品牌:MCE
型号:HY-10219
规格:10mg
价格:550.000
18957101040
产品详情

Rapamycin (Sirolimus) 是一种有效且特异性的 mTOR 抑制剂,作用于 HEK293 细胞,抑制 mTOR,IC50 为 0.1 nM。Rapamycin 与 FKBP12 结合且抑制 mTORC1。Rapamycin 还是一种自噬 (autophagy) 激活剂,免疫抑制剂。


生物活性
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].
IC50 & Target[1][2]
mTOR:0.1 nM (IC50, in HEK293 cells )

 


体外研究
(In Vitro)


Rapamycin (12.5-100 nM; 24 hours) treatment exerts modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines (A549, SPC-A-1, 95D and NCI-H446 cells) tested, achieving about 30-40% reduction in cell proliferation at 100 nM vs. ~10% reduction at 12.5 nM[3].
Lung cancer cell line 95D cells are exposed to Rapamycin (10 nM, 20 nM) and RP-56976 (1 nM, 10 nM) alone or in combination (Rapamycin 20 nM+ RP-56976 10 nM). After 24 hours exposure to Rapamycin or RP-56976 alone does not significantly alter the level of expression or phosphorylation of ERK1/2, whereas cells treated with the combination of Rapamycin with RP-56976 exhibit a marked reduction in the phosphorylation levels of ERK1/2[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3]

Cell Line: Lung cancer cell lines A549, SPC-A-1, 95D and NCI-H446
Concentration: 12.5 nM, 25 nM, 50 nM, 100 nM
Incubation Time: 24 hours
Result: Treatment exerted modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines.



体内研究
(In Vivo)


Rapamycin (2.0 mg/kg; intraperitoneal injection; every other day; 28 days) alone has a moderate inhibitory effect. However, the combination of Metformin and Rapamycin exerts a significantly increased inhibition of tumor growth compared with the control group, the Rapamycin monotherapy group and the Metformin monotherapy group[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 24 male nu/nu mice aged 4-5 week old (15-20 g)[4]
Dosage: 2.0 mg/kg
Administration: Intraperitoneal injection; every other day; 28 days
Result: Had a moderate inhibitory effect in monotherapy group. The combination with Metformin exerted a significantly increased inhibition of tumor growth.



Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01885689 City of Hope Medical Center|National Cancer Institute (NCI)
Adult Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Therapy-Related Myelodysplastic Syndrome
February 10, 2014 Phase 2
NCT04893291 Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Artery Disease|Coronary Artery Stenosis
October 30, 2021 Not Applicable
NCT03582878 Institute for Clinical and Experimental Medicine
Diabetes Mellitus, Type 1
January 1, 2004 Phase 4

分子量
914.17
CAS 号
53123-88-9
Formula
C51H79NO 13
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

溶解性数据


In Vitro: 

DMSO : 125 mg/mL (136.74 mM; Need ultrasonic)

Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic)

配制储备液
浓度溶剂体积质量 1 mg 5 mg 10 mg
1 mM 1.0939 mL 5.4694 mL 10.9389 mL
5 mM 0.2188 mL 1.0939 mL 2.1878 mL
10 mM 0.1094 mL 0.5469 mL 1.0939 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% EtOH    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.73 mM); Suspended solution

  • 2.

    请依序添加每种溶剂: 10% EtOH    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (2.73 mM); Suspended solution; Need ultrasonic

  • 3.

    请依序添加每种溶剂: 10% EtOH    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.73 mM); Suspended solution

  • 4.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (2.28 mM); Clear solution

  • 5.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (2.28 mM); Suspended solution; Need ultrasonic

  • 6.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (2.28 mM); Clear solution



参考文献


[1]. Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282(18), 13395-13401.

[2]. Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25;30(34):11388-97.

[3]. Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30:28.

[4]. Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15(2):1811-1816.



选择区号
隐私协议
×

平台信息提交-隐私协议

● 隐私权政策

我们致力于保护您在使用本网站时所提供的隐私、私人资料以及个人的资料(统称“个人资料”)。使我们在收集、使用、储存和传送个人资料方面符合(与个人资料隐私有关的法律法规)及消费者保护方面的最高标准。为确保您对本网站在处理个人资料上有充分信心,您切要详细阅读及理解隐私政策的条文。 本网站(下称“我们”)尊重并保护用户隐私, 特别时您一旦使用本网站,将被视为接受、同意、承诺和确认本隐私协议;您在自愿下连同所需的同意向我们披露个人资料;您会遵守本隐私政策的任何修改;您同意我们的相关业务人员就您可能会感兴趣的产品和服务与您联络(除非您已经表示不想收到该等讯息)。被收集的个人资料的种类经您的同意、我们会收集、管理和监控个人资料。

1、 适用范围

为用户提供更好、更优、更个性化的服务是本网站坚持不懈的追求,也希望通过我们提供的服务可以更方便您的需求。本隐私权政策适用于本网站提供的所有关于信息收集的服务,您访问本网站及使用本网站提供的服务均使用本隐私权政策。

2、 我们收集哪些信息

为了向您提供我们的各项服务,您需要提供个人资料信息,其中包括个人资料和不具名的资料,包括但不限于:个人资料(您的姓名、性别、年龄、出生日期、电话号码、传真号码、住址或通讯地址、电子邮箱地址等)。

3、 我们如何使用收集到的信息

收集个人资料和不具名的资料目的及用途如下:通过本网站向您提供我们的各项服务;当您使用我们的网站时,能辨认以及确认您的身份;让您使用本网站时得到为您而设的服务;本网站的相关业务人员有需要时可以与您联系;让您在使用本网站时更加方便;您提供给我们的个人资料及不具名资料,只保留到搜集的目的已达到的时候,除非因适用的法律法规之规定而继续保留。个人资料的拥有权及披露在我们网站上所收集的一切资料都由我们所拥有,不会出租或出售给任何无关的第三方。

4、 我们如何保护信息

对于个人资料的保护,我们实施妥适的实物、电子、管理的措施来保护和保障您的个人资料的安全。我们尽力确保通过本网站所收集的任何个人资料皆免于任何与我们无关的第三者的滋扰。我们采取的安全措施不限于: 实物措施:存有您个人资料的记录会被存放在有锁的地方 电子措施:存有您个人资料的电脑数据会被存放在受严格登录限制的电脑系统和存储媒体上 管理措施:只有经过我们授权的职员才能接触到您的个人资料,这些职员需要遵守我们个人资料保密的内部规则 若您知悉本网站上有任何安全方面的漏洞,请及时联络我们,使我们可以尽快采取妥适的行动;尽管实施了上述安全措施,我们不能保证资料在互联网上的输送绝对安全,因此我们不能绝对保证您通过本网站提供给我们的个人资料及不具名的资料在一切时候都是安全的。对任何因未经授权而接触您个人资料所发生的事件我们一概不承担责任,于这方面产生或导致的任何损失和损害,我们也不负责赔偿。

5、 未成年人保护法

未成年人在无任何家长或监护人相信有未成年人在未经家长或监护人批准或同意下向本网站提供了个人资料,请及时联系本网站所公示电话及客服电话等,以确保资料被除去。

6、 隐私政策的修定与生效

随着本网站的服务范围扩大,我们可能适时修订《法律声明及隐私权政策》,该等修订构成本《法律声明及隐私权政策》的一部分。为避免您不能及时获知该等修订,请您经常阅读本《法律声明及隐私权政策》。无论何种方式,如您继续使用我们的服务,即表示同意受经修订的本《法律声明及隐私权政策》的约束。